Media

April 17, 2025

Virax COO, Nigel McCracken, Discusses New Data on T Cell Exhaustion in Post-Acute Infection Syndromes with PharmExec.com in Latest Article.

March 18, 2025

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 13, 2025

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 12, 2025

Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”

Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos,

March 5, 2025

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 4, 2025

Tune in now to listen to Dr. Nigel McCracken talk about “The Power of T Cell Immunology: Early Diagnosis, Immunotherapy, & the Future of Global Health” on the Finding Genius podcast

March 3, 2025

Join us for Inside Precision Medicine’s FREE State of Precision Medicine Summit on Wednesday, March 5th, 2025.

One of the key highlights is the “State of Molecular Diagnostics” panel at 2:30pm EST, featuring industry leaders including Virax Biolab’s COO, Dr Nigel McCracken, and moderated by North American

February 26, 2025

“Preparing for Potential Vaccine Regulatory Changes”: Virax CEO, James Foster, discusses how the industry is preparing for potential regulatory changes to vaccine policy

Article by Mike Hollan

February 25, 2025

Virax Biolabs Believes Technology Aligns with Unites States Department of Health and Human Services’ Transparency Priority on Vaccine Efficacy

February 21, 2025

“What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances”: Industry leaders including Virax CEO, James Foster, share their expectations for the year ahead

Article by Eleanor Malone

February 19, 2025

“Global Launch Strategies in the Current Political Climate”: Virax CEO, James Foster, discusses how global launches are being impacted by changing geopolitical conditions